Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 4

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

Philip Kern · with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCT05051436

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 35–65 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 4
Target enrollment
96
US sites recruiting
1
Study start
December 13, 2021
Record last updated
August 31, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.

Being studied: Mirabegron 50 MG; Tadalafil 10 MG; Placebo

Conditions: Pre-diabetes; Obesity

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Hemoglobin A1C between 5.7 and 6.4
  • Body mass index between 27 and 45

Exclusion Criteria

  • Diabetes
  • Chronic use of any antidiabetic medications
  • Any unstable medical condition
  • Use of steroids or daily use of NSAIDS
  • History of chronic inflammatory conditions
  • Use of anticoagulants
  • Contraindications to the use of mirabegron or tadalafil
  • Any condition deemed risky by the study physician

Recruiting US locations

  • University of Kentucky

    Lexington, KY 40536

    Site contact: Zach Leicht · 859-218-1397 · zachary.leicht@uky.edu

Study contacts (from the official record)

  • Zach Leicht · 859-218-1397 · zachary.leicht@uky.edu
  • Philip Kern, M.D. · 859-218-1394 · pake222@uky.edu
All weight loss studies in Kentucky →
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in… (NCT05051436) | Bored Studies